Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS (KRAS mutated in ~40% of CRCs) or RAF (BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13,14,15].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“Since only 30%–50% of colorectal cancers have KRAS mutations [4,18,21], there has been speculation that the detection of KRAS mutation may portend a worse prognosis.”
BackgroundHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095 · cited 1×
“addition, miRNA expression is often lost in cancer because they tend to be located in genomic regions that are frequently lost during cancer development [67].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 4×
“The reduced expression of let-7 in cancer tissues corresponds to significantly higher levels of KRAS mRNA [70].”
BackgroundInfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690 · cited 1×
“Given that EGFR, a transmembrane receptor tyrosine kinase, is overexpressed in 25%–75% of colorectal tumors [38,39], a significant proportion of patients that may benefit from anti-EGFR agents may also have KRAS mutation.”
BackgroundChemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Cited by
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
“Anemia 0 (0) 1 (20) 0 (0) 0 (0) 6 (5) 5 (4) 0 (0) 3 (27) 15 (11)”
Self-citationBedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond
Vaidyanathan, R., Soon, R. H., Zhang, P., Jiang, K., & Lim, C. T. (2018) · Lab on a Chip · doi:10.1039/c8lc00684a · Cited by 259
Pathological Features and Prognostication in Colorectal Cancer
Chen, K., Collins, G., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 242
“KRAS mutations contribute to unregulated cell growth, ultimately leading to the expansion of tumour cell growth [85,86].”
BackgroundGermann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M., Boucher, D. M., Sorrell, D. A., Martinez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 233
“Activating mutations of RAS family members KRAS and NRAS are found in approximately 30% of all human cancers, with particularly high incidence in pancreatic and colorectal cancer (1, 2).”
BackgroundSerebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
Harb, W., Fan, A., Tran, T., Danila, D. C., Keys, D., Schwartz, M., & Ionescu-Zanetti, C. (2013) · Translational Oncology · doi:10.1593/tlo.13367 · Cited by 205
“For CK staining, we used antibody clone CK3-6H5, a pancytokeratin-specific antibody likely to recognize all simple epithelium CKs; it has been shown to bind CKs [7,8,13].”
BackgroundMethodArvelo, F. A., Sojo, F., & Cotte, C. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.520 · Cited by 198
“The mutations on the K-ras oncogene are produced during an even more advanced stage, preferentially affecting codons 12 and 13, and are found on up to 40% of colorectal tumours [49].”
BackgroundQian, Y., Wang, X., Liu, Y., Li, Y., Colvin, R. A., Tong, L., Wu, S., & Chen, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.008 · Cited by 149
“The finding that Kras A549 cells show macropinocytosis is significant because up to 20% of all human cancers express oncogenic Kras mutations [39], which are known to upregulate glucose metabolism [40,41].”
BackgroundTolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., Patnaik, A., Jones, S. F., Rasco, D. W., Cox, D. S., Durante, M., Bellew, K. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu482 · Cited by 137
“Both pathways can be co-activated by oncogenic mutations in RAS, which have been identified in approximately 17%–25% of human cancers, including up to 90% of pancreatic tumors [4].”
BackgroundImportant molecular genetic markers of colorectal cancer
Kudryavtseva, A. V., Lipatova, A. V., Zaretsky, A. R., Moskalev, A. A., Fedorova, M. S., Rasskazova, A. S., Shibukhova, G. A., Snezhkina, A. V., Kaprin, A. D., Alekseev, B. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9796 · Cited by 114
“Mutation status of KRAS, NRAS, BRAF and PIK3CA genes can be used as a prognostic and especially as predictive marker: the presence of a mutation in the hotspots of any of these genes is associated with a potential resistance to inhibitors of receptor tyrosine kinases, as well as to monotherapy with mTOR inhibitors [12…”
BackgroundMicroRNAs as novel biomarkers for colorectal cancer: New outlooks
Shirafkan, N., Mansoori, B., Mohammadi, A., Shomali, N., Ghasbi, M., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.046 · Cited by 124
Valentini, P., Fiammengo, R., Sabella, S., Gariboldi, M., Maiorano, G., Cingolani, R., & Pompa, P. P. (2013) · ACS Nano · doi:10.1021/nn401757w · Cited by 115
Ferreira, A. I., Pereira, F. D. S., Reis, C. A., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11142183 · Cited by 123
“In mammalian cells, KRAS is normally found in its inactive state—GDP-bound [4,18,19].”
BackgroundKurth, I., Yamaguchi, N., Andreu-Agulló, C., Tian, H. S., Sridhar, S., Takeda, S., Gonsalves, F. C., Loo, J. M., Barlas, A., Manova-Todorova, K. O., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi7511 · Cited by 99
“Quantitation and statistics were calculated using Microsoft Excel, GraphPad Prism 8.1, and RStudio 1.0.143.”
InfluentialWang-Bishop, L., Chen, Z., Gomaa, A. R., Lockhart, A. C., Salaria, S. N., Wang, J., Lewis, K. B., Ecsedy, J., Washington, K. M., Beauchamp, R. D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.10.030 · Cited by 95
Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02491-w · Cited by 102
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS ( KRAS mutated in ~40% of CRCs) or RAF ( BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13–15].”
The Genomics of Colorectal Cancer in Populations with African and European Ancestry
Myer, P. A., Lee, J. K., Madison, R. W., Pradhan, K., Newberg, J. Y., Isasi, C. R., Klempner, S. J., Frampton, G. M., Ross, J. S., Venstrom, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0813 · Cited by 91
“50%), which has been associated with increased disease progression and decreased survival (27).”
BackgroundKRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 86
“KRAS mutations have also been associated with poor overall survival and increased tumor aggressiveness [25].”
BackgroundUdager, A. M., McHugh, J. B., Betz, B. L., Montone, K. T., LiVolsi, V. A., Seethala, R. R., Yakirevich, E., Iwenofu, O. H., Perez‐Ordoñez, B., DuRoss, K. E., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4750 · Cited by 74
“In colorectal cancer, KRAS mutations are an important negative predictor of response to targeted anti-EGFR therapy [22].”
BackgroundApplication of nanomaterials in the bioanalytical detection of disease-related genes
Zhu, X., Li, J., He, H., Huang, M. J., Zhang, X., & Wang, S. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.04.069 · Cited by 80
Soleimani, A., Rahmani, F., Saeedi, N., Ghaffarian, R., Khazaei, M., Ferns, G. A., Avan, A., & Hassanian, S. M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29268 · Cited by 71
“Genetic analyses of oncogenic KRAS shows KRAS mutation is one of the early processes in CRC progression occurring in 30% to 40% of colorectal cancers.(59) Oncoprotein KRAS has a significant role in tumor development via modulation of various miRNAs including miR‐200c, miR‐221, and miR‐222 in CRC cells lines, HCT116(60…”
BackgroundCao, Y., Deng, S., Yan, L., Gu, J., Jiang, L., Wu, K., & Cai, K. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03566-2 · Cited by 65
Cazzanelli, G., Pereira, F. D. S., Alves, S., Francisco, R., Azevedo, L., Carvalho, P. D., Almeida, A. F., Côrte‐Real, M., Oliveira, M. J., Lucas, C., et al. (2018) · Cells · doi:10.3390/cells7020014 · Cited by 62
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 69
“Similarly, in CRC, patients with KRAS mutation act as primary risk category patients and need better treatment management [124].”
BackgroundExploring Dysregulated Signaling Pathways in Cancer
Nisar, S., Hashem, S., Macha, M. A., Yadav, S. K., Muralitharan, S., Therachiyil, L., Sageena, G., Al‐Naemi, H. A., Haris, M., & Bhat, A. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115095937 · Cited by 60
Agarwal, S., Chakravarthi, B. V. S. K., Behring, M. P., Kim, H., Chandrashekar, D. S., Gupta, N., Bajpai, P., Elkholy, A., Balasubramanya, S. A. H., Hardy, C., et al. (2020) · Cancers · doi:10.3390/cancers12040772 · Cited by 61
“In 35–45% of CRCs, the guanosine triphosphate/guanosine diphosphate GTP/GDP binding protein, ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), is mutated, and this alteration affects treatment strategies [6].”
BackgroundZhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08108-9 · Cited by 54
“It was reported 30–50% of CRC harbor KRAS mutations, and KRAS mutations in CRC have been associated with poorer survival and increased tumor aggressiveness [20].”
BackgroundWeisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., Nelson, E. A., Cowens, K. B., Christie, A. L., Mitsiades, C. S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.149 · Cited by 54
RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy
Osumi, H., Shinozaki, E., Suenaga, M., Matsusaka, S., Konishi, T., Akiyoshi, T., Fujimoto, Y., Nagayama, S., Fukunaga, Y., Ueno, M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30106 · Cited by 52
“For example, KRAS exon 2 mutation, especially the glycine to valine mutation in codon 12 of the Ki-ras gene, was shown as a poor prognostic factor in patients with Duke’s C cancer and was associated with 50% increased of relapse or death.(19,20) However, results have been controversial about mutations in codon 13.”
BackgroundImmune characterization of metastatic colorectal cancer patients post reovirus administration
Parakrama, R. Y., Fogel, E. J., Chandy, C., Augustine, T. A., Coffey, M. C., Tesfa, L., Goel, S., & Maitra, R. (2020) · BMC Cancer · doi:10.1186/s12885-020-07038-2 · Cited by 52
Mechanisms of immunogenicity in colorectal cancer
Sillo, T. O., Beggs, A. D., Morton, D. G., & Middleton, G. (2019) · British journal of surgery · doi:10.1002/bjs.11204 · Cited by 53
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 51
Grasso, S., Tristante, E., Saceda, M., Carbonell, P., Mayor-López, L., Carballo-Santana, M., Carrasco‐García, E., Rocamora‐Reverte, L., García-Morales, P., Carballo, F., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.08.011 · Cited by 51
“The RAF/MEK/ERK pathway has attracted much attention in the search for new chemotherapeutic agents, due to both the high frequency of KRAS (40%) and BRAF (10%) mutations identified in colon tumours [3–5] and the essential role of this pathway in promoting cell proliferation and survival [6].”
BackgroundBao, C., Conde, J., Curtin, J. F., Artzi, N., Tian, F., & Cui, D. (2015) · Scientific Reports · doi:10.1038/srep12297 · Cited by 48
MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers
Angius, A., Pira, G., Scanu, A. M., Uva, P., Sotgiu, G., Saderi, L., Manca, A., Serra, C., Uleri, E., Piu, C., et al. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.35269 · Cited by 47
“KRAS gene mutation analysis was performed on codons 12 and 13 of exon 2 and codons 59 and 61 of exon 3, which are known to harbor the most frequent and significant activating mutations for this gene [17], resulting in impaired intrinsic and GTPase-activating protein (GAP)–mediated GTP hydrolysis and leading to elevate…”
MethodYe, Z., Qiu, M., Tang, T., Wang, F., Zhou, Y., Lei, M., Guan, W., & He, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2727 · Cited by 50
Dual role of heme iron in cancer; promotor of carcinogenesis and an inducer of tumour suppression
Gamage, S. M. K., Lee, K. T., Dissabandara, L., Lam, A. K.-Y., & Gopalan, V. (2021) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2021.104642 · Cited by 46
Li, Y., Eresen, A., Shangguan, J., Yang, J. Y., Benson, A. B., Yaghmai, V., & Zhang, Z. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03354-z · Cited by 44
Hongo, T., Yamamoto, H., Jiromaru, R., Nozaki, Y., Yasumatsu, R., Hashimoto, K., Yoneda, R., Sugii, A., Taguchi, K., Masuda, M., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001566 · Cited by 45
The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
Won, D. D., Lee, J. I., Lee, I. K., Oh, S., Jung, E. S., & Lee, S. H. (2017) · BMC Cancer · doi:10.1186/s12885-017-3381-7 · Cited by 44
“KRAS mutations are identified in 30–50% of CRCs and are usually point mutations that occur in codons 12 and 13, less often in codon 61, and very infrequently at other sites such as codons 59, 146, 19, or 20 [5, 7].”
Current and future biomarkers in the treatment of colorectal cancer
Cuyle, P.-J. A., & Prenen, H. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1262996 · Cited by 42
In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging
Yosef, H. K., Mavarani, L., Maghnouj, A., Hahn, S. A., El‐Mashtoly, S. F., & Gerwert, K. B. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8875-z · Cited by 40
“KRAS mutation also is reported to be predictive for poor prognosis and low survival rate in cancer [22,25,29].”
Low penetrance genetic polymorphisms as potential biomarkers for colorectal cancer predisposition
Tan, S. C. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3010 · Cited by 41
“Among the three human RAS genes, the role of KRAS is most apparent in colorectal cancer.(37) Approximately 30–40% of colorectal carcinomas harbor KRAS mutations, typically at exon 2 (codons 12 and 13) and exon 3 (codon 61).”
BackgroundVarshavi, D., Varshavi, D., McCarthy, N., Veselkov, K., Keun, H. C., & Everett, J. R. (2020) · Metabolomics · doi:10.1007/s11306-020-01674-2 · Cited by 40
Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies
Yang, Z., Wang, X., Zhou, H., Jiang, M., Wang, J., & Sui, B. (2024) · Cancer Management and Research · doi:10.2147/cmar.s481656 · Cited by 44
Bağcı, B., Sari, M., Karadayı, K., Turan, M., Özdemir, Ö., & Bağcı, G. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160624 · Cited by 40
“KRAS which is one of the most frequently studied oncogene plays crucial roles both in colorectal cancer screening and determination of the treatment method [6].”
BackgroundWangefjord, S., Sundström, M., Zendehrokh, N., Lindquist, K., Nodin, B., Jirström, K., & Eberhard, J. (2013) · Biology of Sex Differences · doi:10.1186/2042-6410-4-17 · Cited by 36
“Approximately 40% of all colorectal tumours harbour a KRAS mutation, predominantly occurring in codon 12 or 13 [2].”
Kubota, Y., Han, Q., Morinaga, S., Tsunoda, T., & Hoffman, R. M. (2023) · In Vivo · doi:10.21873/invivo.13310 · Cited by 37
Viable pigs with a conditionally-activated oncogenic KRAS mutation
Li, S., Edlinger, M., Saalfrank, A., Flisikowski, K., Tschukes, A., Kurome, M., Zakhartchenko, V., Keßler, B., Saur, D., Kind, A., et al. (2015) · Transgenic Research · doi:10.1007/s11248-015-9866-8 · Cited by 39
Maus, M. K. H., Grimminger, P., Mack, P. C., Astrow, S. H., Stephens, C. A., Zeger, G. D., Hsiang, J., Brabender, J., Friedrich, M., Alakus, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.010 · Cited by 38
“Mutations in the KRAS oncogene are an early and central event n the pathogenesis of CRC and are associated with a worse progosis [4,5].”
BackgroundResultHongo, T., Yamamoto, H., Jiromaru, R., Yasumatsu, R., Kuga, R., Nozaki, Y., Hashimoto, K., Matsuo, M., Wakasaki, T., Tamae, A., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00868-w · Cited by 33
Autophagy regulates Selumetinib (AZD6244) induced-apoptosis in colorectal cancer cells
Grasso, S., Pereira, G. J. S., Palmeira-dos-Santos, C., Calgarotto, A. K., Martínez-Lacaci, I., Ferragut, J. A., Smaili, S. S., & Bincoletto, C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.043 · Cited by 32
Rho GTPases as Key Molecular Players within Intestinal Mucosa and GI Diseases
Pradhan, R., Ngo, P. A., Martínez-Sánchez, L. D. C., Neurath, M. F., & López-Posadas, R. (2021) · Cells · doi:10.3390/cells10010066 · Cited by 36
“In humans, RAS mutations were identified in 30% to 50% of colorectal cancers [30,31].”
BackgroundCioce, M., & Fazio, V. M. (2021) · Cancers · doi:10.3390/cancers13040700 · Cited by 34
“It is estimated that 40% of CRC patients bear K-Ras mutations and are non-responsive to cetuximab [160,161].”
BackgroundFibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer
Göke, F., Göke, A., von Mäßenhausen, A., Franzen, A., Sharma, R. K., Kirsten, R., Böhm, D., Kristiansen, G., Stenzinger, A., Wynes, M. W., et al. (2013) · Digestion · doi:10.1159/000355018 · Cited by 35
Wyss, L. A., Nilforoushan, A., Eichenseher, F., Suter, U., Blatter, N., Marx, A., & Sturla, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5100542 · Cited by 31
Tumor location as a novel high risk parameter for stage II colorectal cancers
Wang, B., Yang, J., Li, S., Lv, M., Chen, Z., Li, E., Yi, M., & Yang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179910 · Cited by 37
Mardinian, K., Okamura, R., Kato, S., & Kurzrock, R. (2019) · International Journal of Cancer · doi:10.1002/ijc.32510 · Cited by 28
“KRAS is also present in 30–40% of all colorectal cancer cases and is associated with decreased survival.(1,2) Investigation of molecular alterations in cancerous tumors has created a new wave of personalized cancer medicine that uses targeted cancer therapies matched to a patient’s specific molecular alterations.”
BackgroundZhou, J., Li, Q., & Cao, Y. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3665 · Cited by 29
Forzati, F., Martino, M. D., Esposito, F., Sepe, R., Pellecchia, S., Malapelle, U., Pellino, G., Arra, C., & Fusco, A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3158-z · Cited by 27
Clinico-pathological Study of K-ras Mutations in Colorectal Tumors in Saudi Arabia
Zahrani, A., Kandil, M. S., Badar, T., Abdelsalam, M. G. A., Al-Faiar, A., & Ismail, A. A. (2014) · Tumori Journal · doi:10.1177/1430.15819 · Cited by 27
Kodaz, H., Hacıbekiroğlu, İ., Erdoğan, B., Türkmen, E., Tozkır, H., Albayrak, D., Uzunoğlu, S., & Çiçin, İ. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.448 · Cited by 26
Gene Silencing Using Multifunctionalized Gold Nanoparticles for Cancer Therapy
Fernandes, A. R., & Baptista, P. V. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6646-2_19 · Cited by 26
Tanjak, P., Chaiboonchoe, A., Suwatthanarak, T., Acharayothin, O., Thanormjit, K., Chanthercrob, J., Suwatthanarak, T., Wannasuphaphol, B., Chumchuen, K., Suktitipat, B., et al. (2023) · Cancers · doi:10.3390/cancers15041098 · Cited by 27
“CRC patients with KRASmut revealed a poor prognosis [4], liver metastases [5], and tumor aggressiveness [6], compared to patients with KRASwt.”
ResultPAICS as a potential target for cancer therapy linking purine biosynthesis to cancer progression
Ma, A. H., & Xiong, X. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122070 · Cited by 24
Umelo, I. A., Costanza, B., & Castronovo, V. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9710-0 · Cited by 25
“Following ex vivo perfusion and biotinylation of colorectal cancer (CRC) tissue, we also identified two potential clinically relevant targets, NGAL and GW112 [152].”
BackgroundInfluentialKRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer
Yarom, N., Gresham, G. K., Boame, N., & Jonker, D. J. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.05.004 · Cited by 23
Zhou, X., Kang, J., Zhang, L., & Yue, C. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04549-0 · Cited by 24
“KRAS-mutant CRCs are more aggressive, refractory to selected treatment strategies, such as antiEGFR therapy, and correlated with poorer survival [5].”
BackgroundPrice, K. A. R., & Cohen, E. E. W. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.018 · Cited by 24
“In lung cancer, activating mutations in EGFR are known to be the primary predictor of benefit from erlotinib, gefitinib, and afatinib [18,19], and in colon cancer, the presence of a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is predictive of primary resistance to EGFR-targeted therapy [20].”
BackgroundKRAS mutations are negatively correlated with immunity in colon cancer
Fu, X., Wang, X., Duanmu, J., Li, T., & Jiang, Q. (2020) · Aging · doi:10.18632/aging.202182 · Cited by 20
“In addition, KRAS mutations are predictive markers for breast, lung, ovarian, head/neck, and pancreatic cancers [4, 8, 9, 11].”
BackgroundIP3 Receptor Biology and Endoplasmic Reticulum Calcium Dynamics in Cancer
Parys, J. B., Bultynck, G., & Vervliet, T. (2021) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-67696-4_11 · Cited by 24
Fattahi, F., Kiani, J., Alemrajabi, M., Soroush, A., Naseri, M., Najafi, M., & Madjd, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02002-x · Cited by 22
Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
Peres, C., Matos, A. I., Carreira, B., Moura, L. I. F., Kleiner, R., Vaskovich‐Koubi, D., Reshef, K., Dulberg, S., Verdial, M., Conniot, J., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401749 · Cited by 21
Lee, S., Heinrich, E. L., Lu, J., Lee, W., Choi, A. H., Luu, C., Chung, V. M., Fakih, M., & Kim, J. (2015) · Pancreas · doi:10.1097/mpa.0000000000000379 · Cited by 26
“com/MPA/A384).(22) Our previous work has shown that silencing K-ras does not interfere with EGFR-mediated ERK phosphorylation.”
BackgroundSelf-citationRao, Q., Zhang, Q., Zheng, C., Dai, W., Zhang, B., Ionescu‐Zanetti, C., Lin, Z., & Zhang, L. (2017) · PubMed Central · Cited by 19
KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Choi, S., Kim, J. K., Chen, C., Wu, C., Marco, M. R., Barriga, F. M., O’Rourke, K. P., Pelossof, R., Qu, X., Chang, Q., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0994 · Cited by 22
Self-citationPeiris, D., Ossondo, M., Fry, S. A., Loizidou, M., Smith‐Ravin, J., & Dwek, M. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138345 · Cited by 19
Molecular understanding of lung cancers–A review
Singh, C. R., & Kathiresan, K. (2014) · Asian Pacific Journal of Tropical Biomedicine · doi:10.12980/apjtb.4.2014c597 · Cited by 18
Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
Lee, J., Ahn, J., Park, W. S., Choe, E. K., Kim, E. Y., Shin, R., Heo, S., Jung, S., Kim, K., Chai, Y. J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010111 · Cited by 18
“Mutations of KRAS are found in 30–50% of CRCs and they are usually point mutations, primarily in codons 12 and 13 [31].”
BackgroundRasmy, A. A., Fayed, A., Omar, A., & Fahmy, N. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.05.04 · Cited by 19
“(3) recognized HRAS and KRAS as the first 2 RAS genes from the revisions of 2 viruses initiating malignancy (Harvey sarcoma virus and Kirsten sarcoma virus).”
BackgroundJinrong, C., Xavier, H. W., Chen, D., Liu, Y., Li, H., & Bian, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690501 · Cited by 20
In-Gene Quantification of O6-Methylguanine with Elongated Nucleoside Analogues on Gold Nanoprobes
Trantakis, I. A., Nilforoushan, A., Dahlmann, H. A., Stäuble, C. K., & Sturla, S. J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03599 · Cited by 18
Gao, X., Yu, G. Y., Hong, Y. G., Lian, W., Chouhan, H. S., Xu, Y., Liu, L., Bai, C. G., & Zhang, W. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1377-1 · Cited by 18
Fernández Montes, A., Alonso Orduña, V., Asensio Martínez, E., Rodríguez Salas, N., Torres, E., Cacho Lavín, D., Rodríguez Alonso, R. M., Falcó, E., Oliva, J. C., Cirera, L., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad117 · Cited by 17
Chang, L., Fan, C., Tseng, W., & Hua, C. (2019) · Cancer Biomarkers · doi:10.3233/cbm-190828 · Cited by 17
“Keap1 can be degraded, as it is bound by p62 [41], possibly contributing to the similar protein levels of Nrf2 in the tumor and normal tissues of CRC with or without metastasis.”
A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases
Kim, K., Yu, J. I., Park, H. C., Yoo, G. S., Lim, D. H., Noh, J. M., & Jeong, W. K. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.09.003 · Cited by 16
Al-Qahtani, W. S., Al-Olayan, E. M., Albani, F. G., Suliman, R. S., Aljarba, N. H., Al-Humaidhi, E. M. H., Almurshedi, A. S., Domiaty, D. M., Alduwish, M. A., Al‐Otaibi, A. M., et al. (2020) · Global Medical Genetics · doi:10.1055/s-0040-1714415 · Cited by 16
Afolabi, H. A., Salleh, M. S. M., Zakarıa, Z., Ch’ng, E. S., Nafi, S. N. M., Aziz, A. A. A., Wada, Y., & Irekeola, A. A. (2022) · BioMed Research International · doi:10.1155/2022/5824183 · Cited by 17
“KRAS gene mutations, which function as an active onco-gene, are found in 35 to 45 percent of CRC cases globally [50, 101 – 103].”
KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells
Patankar, M., Eskelinen, S. M., Tuomisto, A., M�kinen, M. J., & Karttunen, T. J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10693 · Cited by 20
Cheung, B. M. F., Lau, K.-S., Lee, V. H.-F., Leung, T., Kong, F., Luk, M., & Yuen, K.-K. (2021) · Radiation Oncology Journal · doi:10.3857/roj.2021.00311 · Cited by 17
“Indeed, lung cancers with KRAS mutations are characterized by poor prognosis and treatment resistance and same has been demonstrated in colorectal cancers as well [44,45].”
BackgroundXu, K., Wang, J., Gao, J., Di, J., Jiang, B., Chen, L., Wang, Z., Wang, A., Wu, F., Wu, W., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4961 · Cited by 15
“Although still controversial, several studies have demonstrated that KRAS mutation in colorectal carcinoma is correlated to unfavorable survival and enhanced tumor aggressiveness (11,12).”
ResultColon Cancer Combined with Obesity Indicates Improved Survival - Research on Relevant Mechanism
Zhou, Y., Wei, X., Pan, Y., Min, Z., Xu, J., & Yu, B. (2020) · Aging · doi:10.18632/aging.103972 · Cited by 15
“KRAS, TP53 and PIK3CA were important gene mutations in colon cancer that associated with progression and prognosis [17, 18].”
BackgroundKamran, S., Seyedrezazadeh, E., Shanehbandi, D., Asadi, M., Zafari, V., Shekari, N., Namvar, L., & Zarredar, H. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00667-1 · Cited by 16
Patil, H., Korde, R., & Kapat, A. (2013) · Medical Oncology · doi:10.1007/s12032-013-0617-5 · Cited by 15
“The presence of a glycine residue in codon 12 appears to be critical for normal function of ras proteins [8].”
BackgroundYao, T., Zhu, J., Peng, D.-F., Cui, Z., Zhang, C., & Lu, P. (2015) · Tumor Biology · doi:10.1007/s13277-015-3237-1 · Cited by 13
“Mutations in KRAS will result in a constitutively activated RAS protein, which activates RAS-mediated downstream signaling (mainly ERK/MAPK) to endorse cancer cell survival, proliferation, and apoptosis resistance [22].”
BackgroundZhou, J., Zheng, B., Ji, J., Shen, F., Min, H., Liu, B., Wu, J., & Zhang, S. (2014) · Tumor Biology · doi:10.1007/s13277-014-2961-2 · Cited by 13
KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer
Kodaz, H., Tastekin, E., Erdoğan, B., Hacıbekiroğlu, İ., Tozkır, H., Gürkan, H., Türkmen, E., Demirkan, B., Uzunoğlu, S., & Çiçin, İ. (2016) · Balkan Medical Journal · doi:10.5152/balkanmedj.2016.150610 · Cited by 13
Metadata
- Authors
- Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J.
- Affiliations
- City Of Hope National Medical Center (US)
- University of Southern California (US)
- Division of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 11597, USA
- Corresponding author
- Arrington, Amanda K.
- Kim, Joseph
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-09-25
- Volume
- 13
- Issue
- 10
- Pages
- 12153-12168
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3497263
- OpenAlex
- W1991898744
- Cited by
- 244
- References
- 86
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 18 · 2023: 20 · 2022: 16 · 2021: 28 · 2020: 29 · 2019: 22 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 15 · 2014: 20 · 2013: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer, prognostic factors, predictive biomarkers, ras gene family, treatment resistance, tumor aggressiveness, survival
- MeSH terms
- Humans, Polymorphism, Genetic, Prognosis, Colorectal Neoplasms, ras Proteins, MicroRNAs, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


